APA (7th ed.) Citation

YS, C., CY, L., YW, C., SH, H., HY, L., CC, L., . . . HA, H. (2025). Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study. Clinical lymphoma, myeloma & leukemia, 25(12), 885. https://doi.org/10.1016/j.clml.2025.06.011

Chicago Style (17th ed.) Citation

YS, Chang, et al. "Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study." Clinical Lymphoma, Myeloma & Leukemia 25, no. 12 (2025): 885. https://doi.org/10.1016/j.clml.2025.06.011.

MLA (9th ed.) Citation

YS, Chang, et al. "Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study." Clinical Lymphoma, Myeloma & Leukemia, vol. 25, no. 12, 2025, p. 885, https://doi.org/10.1016/j.clml.2025.06.011.